Consistent with this report, Suman et al. have noted that oral administration of withaferin A induces Par-4 accumulation and up-regulates E-cadherin, while down-regulating mesenchymal markers such as β-catenin and vimentin in prostate cancer model97 (Fig. 6A, B). Here, PAWR is linked to prostate cancer.